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Abstract
Introduction
The reported estimates of the economic costs associated 
with  prostate  cancer  screening,  diagnostic  testing,  and 
clinical  staging  are  substantial.  However,  the  resource 
costs  (i.e.,  factors  such  as  physician’s  time,  laboratory 
tests, patient’s time away from work) included in these 
estimates are unknown. We examined the resource costs 
for prostate cancer screening, diagnostic tests, and stag-
ing; examined how these costs differ in the United States 
from costs in other industrialized countries; and estimated 
the cost per man screened for prostate cancer, per man 
given  a  diagnostic  test,  and  per  man  given  a  clinically 
staged diagnosis of this disease.
Methods
We  searched  the  electronic  databases  MEDLINE, 
EMBASE,  and  CINAHL  for  articles  and  reports  on 
prostate  cancer  published  from  January  1980  through 
December  2003.  Studies  were  selected  according  to  the 
following  criteria:  the  article  was  published  in  English; 
the full text was available for review; the study reported 
the resource or input cost data used to estimate the cost 
of prostate cancer testing, diagnosing, or clinical staging; 
and the study was conducted in an established market 
economy. We used descriptive statistics, weighted mean, 
and Monte Carlo simulation methods to pool and analyze 
the abstracted data.
Results
Of 262 studies examined, 28 met our selection criteria 
(15 from the United States and 13 from other industrial-
ized countries). For studies conducted in the United States, 
the pooled baseline resource cost was $37.23 for screening 
with prostate-specific antigen (PSA) and $31.77 for screen-
ing  with  digital  rectal  examination  (DRE).  For  studies 
conducted  in  other  industrialized  countries,  the  pooled 
baseline resource cost was $30.92 for screening with PSA 
and $33.54 for DRE. For diagnostic and staging methods, 
the  variation  in  the  resource  costs  between  the  United 
States and other industrialized countries was mixed.
Conclusion
Because national health resources are limited, a decision 
about whether to invest in early detection of prostate can-
cer requires an understanding of the factors included in 
estimates of the economic cost of this disease. This study 
may benefit health policy makers charged with allocating 
resources for prostate cancer.
Introduction
Prostate cancer is the second most common cancer among 
men worldwide and the fifth most common cancer in the 
world (1,2). Among developed countries, the age-adjusted 
death rate for prostate cancer is highest in Sweden, with 
an estimated rate of 27.7 per 100,000 men, and lowest in 
Japan, with an estimated rate of 5.7 per 100,000 men (3). 
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The United States falls between these two extremes, with 
an estimated rate of 15.8 per 100,000 men.
The  U.S.  Preventive  Services  Task  Force  (USPSTF) 
(www.ahrq.gov/clinic/uspstf.htm)  recommends  screening 
tests for early detection of breast, colorectal, and cervical 
cancers, but screening for prostate cancer remains con-
troversial (4-6). Factors contributing to the controversy 
include the lack of conclusive scientific evidence demon-
strating the effectiveness of screening in reducing mortal-
ity associated with prostate cancer (6) and the absence of 
an international consensus about routine screening (7,8). 
Nevertheless, screening for this disease is widespread (6). 
For example, in 2000, between 34% and 61% of U.S. men 
aged 50 years or older reported having a prostate-specific 
antigen (PSA) test within the previous year (9,10,11).
The reported economic costs associated with screening 
for prostate cancer are substantial and vary widely. For 
example, in 1995 Barry and colleagues estimated the cost 
to  Medicare  of  first-year  PSA  testing  for  men  aged  65 
to 79 years as $2.1 billion (12). In 1994 Lubke and col-
leagues estimated the costs of a first-year national testing 
program using PSA and digital rectal examination (DRE) 
for men aged 50 to 69 years to range from $17.6 to $25.7 
billion (13). In 1990 Optenberg and Thompson estimated 
the costs of a first-year mass screening program for men 
aged 50 through 74 years to range from $11 to $28 billion 
(14). Often, researchers do not provide the components of 
the resource costs (i.e., factors such as physician’s time, 
laboratory  tests,  patient’s  time  away  from  work)  used 
to estimate the economic cost of prostate cancer. When 
resource  costs  are  provided,  they  are  often  presented 
without an explanation as to the types of resources used 
in  calculations  or  how  these  resources  were  measured 
or  valued.  It  is  not  possible  to  determine whether  the 
reported cost of screening includes the costs associated 
with patients’ travel time, time off from work, loss of lei-
sure time, transportation, physicians’ consultation time, 
other medical staff time, medical supplies, office or room 
space, equipment, and patient recruitment. As a result, 
the costs reported from economic studies of prostate can-
cer vary widely.
We reviewed the published articles from 1980 to 2003 in 
order to summarize publicly available data on the resource 
costs used in estimating the economic effects of prostate 
cancer. These resource costs are needed to estimate the 
economic  cost  of  the  disease  accurately.  We  examined 
the resource costs of prostate cancer screening, diagnos-
ing, and staging; examined how resource costs differ in 
the United States from the costs in other countries; and 
estimated a cost per man screened for prostate cancer, per 
man given a diagnostic test, and per man given a clinically 
staged diagnosis of the disease.
Methods
Search and selection processes 
We searched the following computerized electronic data-
bases for articles published from January 1980 through 
December  2003:  MEDLINE  (1980–2003),  EMBASE 
(1980–2003),  and  CINAHL  (1983–2003).  Our  search 
terms  included  prostatic  neoplasms,  prostate  cancer, 
prostate-specific antigen, digital rectal examination, tran-
srectal ultrasound, biopsy, cost, cost analysis, cost-benefit 
analysis, and economic cost. We manually searched the 
bibliographies  of  retrieved  articles  and  reports  to  find 
additional articles.
The following were the preset inclusion criteria for the 
studies selected: the article was published in English; the 
full text was available for review; the resource or input 
cost data used to estimate the cost of screening, diagnos-
ing,  or  clinically  staging  prostate  cancer  were  reported 
in the article; and the study was conducted in countries 
designated as established market economies as defined by 
the World Bank (15).
Data extraction 
From eligible articles and reports, we extracted the fol-
lowing data using a modified extraction method developed 
by the U.S. Guide to Community Preventive Services for 
reviews of economic evaluations (16): study characteristics 
(e.g., researcher[s], year results were published, country 
of study, study setting), participants’ characteristics (e.g., 
age, population screened, number of biopsies performed, 
whether prostate cancer was detected), and resource cost 
characteristics (e.g., year of cost data used in the study, 
currency  denomination,  cost  components).  We  extracted 
the resource costs provided in the articles and attempted 
to contact the researchers for clarification when necessary. 
Any uncertainty about including data from any article was 
resolved by consensus of all coauthors.
2  Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2007/oct/06_0051.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, 
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only 
and does not imply endorsement by any of the groups named above.Data analysis 
Resource  costs  were  separated  into  two  categories: 
those found through studies done in the United States 
and  those  found  through  studies  done  in  other  indus-
trialized countries. For each category, we analyzed the 
resource  costs  for  three  evaluation  methods:  screening, 
diagnosing, and staging. 
Because  our  interest  was  only  in  ascertaining  the 
resource (i.e., input) costs used in calculating the cost of 
each screening procedure, we identified and pooled sepa-
rately the resource costs of serum PSA, free/total PSA (F/
tPSA), complex PSA (cPSA), and DRE. 
For  diagnostic  procedures,  we  identified  and  pooled 
separately  the  resource  costs  of  transrectal  ultrasound 
(TRUS) and biopsy. We defined TRUS as a component of 
diagnostic methods. Because TRUS is used when results of 
PSA, DRE, or both are abnormal, we assumed that TRUS 
serves as a diagnostic procedure to confirm the presence 
or  absence  of  a  prostate  cancer  tumor  before  further 
investigation.  Biopsy  procedures  included  core-needle, 
TRUS-guided,  fine-needle  aspiration,  needle,  and  tran-
srectal needle. The resource costs for performing a biopsy 
represented the combined resource costs of these biopsy 
methods. We also included the resource costs for a urology 
consultation, defined as any consultation or referral to a 
urologist, clinical oncologist, or any other specialist after 
abnormal test results. We reported the resource costs for 
each diagnostic method separately and noted that a urol-
ogy consultation is a process measure, not a diagnostic 
method per se.
For staging methods, we identified the resource costs 
of  clinical  staging  procedures  and  pathologic  or  histo-
logic analysis of specimens. For purposes of our analysis, 
we included in clinical staging procedures computerized 
tomography  (CT),  magnetic  resonance  imaging  (MRI), 
radionuclide bone scan, pelvic lymph node excision and 
analysis,  and  pelvic  echography.  We  also  included  the 
resource cost of pathologic or histologic analysis of a speci-
men as a part of the staging method. We acknowledge that 
this is not a staging method but a process measure; how-
ever, these data were reported separately.
Currency conversion methods 
To allow for greater comparability among studies and 
countries and to standardize the resource costs to 2003 
U.S. dollars, we used three conversion methods: the cost-
to-charge  ratio,  the  Consumer  Price  Index  (CPI)  for  all 
commodities,  and  purchasing  power  parity  (PPP).  For 
the studies conducted in the United States, we used the 
cost-to-charge ratio to convert resource costs reported as 
charges (i.e., prices) into actual costs of providing health 
services (17,18).
We  adjusted  all  resource  costs  to  2003  U.S.  dollars 
using  the  CPI  (i.e.,  measure  of  changes  in  the  average 
price  of  consumer  goods  and  services)  (19).  For  studies 
conducted in other countries, we used the country-specific 
CPI to adjust costs to 2003 country-specific currency. For 
example, we used the Australian CPI to update cost to 
2003 Australian dollars. The CPIs for other countries were 
obtained from the Organisation for Economic Co-operation 
and Development (20).
PPP  converts  currency  units  from  other  countries  to 
U.S. dollars to eliminate differences in price levels among 
countries (21). Using this method, we converted curren-
cies of other countries to U.S. dollars by multiplying the 
adjusted  country-specific  currency  by  the  PPP  rate  for 
each country (22).
Measurement of resource costs used 
Resource categories included direct and indirect costs. 
Direct costs included the resources used in the early detec-
tion of prostate cancer, such as the physician’s consultation 
time, other medical staff’s time, medical supplies, office or 
room space, equipment, and patient recruitment. Indirect 
costs included the patient’s loss of income from time off 
from work, loss of leisure time, transportation cost, and 
travel time. We wrote this article from the societal per-
spective  (17);  that  is,  all  identified  direct  and  indirect 
resource  costs  for  prostate  cancer  prevention  are  taken 
into account, regardless of who might pay for them.
Statistical analysis 
We obtained pooled standardized resource costs by using 
standard descriptive statistics. We estimated the cost per 
man screened and given a clinically staged diagnosis of 
prostate cancer by using the weighted mean method (23). 
For screening methods, the weighted mean cost per man 
screened was computed by multiplying the standardized 
resource cost from each study by the corresponding num-
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ber of men screened, summing this product, and dividing 
by the total number screened. This is expressed as
where j = screening methods (i.e., PSA, F/tPSA, cPSA, 
and DRE); Σ = summation; i = each study; k = number of 
studies, and number tested = the number of men screened 
for prostate cancer. We used the same approach for diag-
nostic  testing  and  staging  methods.  We  computed  95% 
confidence  intervals  (CIs)  for  the  weighted  mean  cost 
estimates. 
Sensitivity analysis 
We  conducted  multivariate  sensitivity  analyses  using 
the  Monte  Carlo  simulation  method  to  appraise  uncer-
tainty in the pooled resource costs (24,25). We fitted prob-
ability  distributions  to  the  resource  cost  data  from  the 
studies included in each evaluation method. Using the fit-
ted distributions, we performed simulations using @Risk 
software  (Palisade  Corporation,  Newfield,  New  York), 
which uses Monte Carlo sampling methods. We performed 
1000 independent simulation trials. On each simulation 
trial, a value for each parameter was drawn from its asso-
ciated distribution and stored for subsequent analysis. The 
results from the simulations are presented as means with 
95% CIs and medians with 25th and 75th percentiles. The 
95% CIs from the simulation were calculated as
Results
Descriptive results 
We identified 262 studies, of which 28 met all inclusion 
criteria (Figure 1). Among these studies, 15 (53.6%) were 
from the United States (14,26-39), 4 (14.3%) from Canada 
(40-43),  4  (14.3%)  from  Sweden  (44-47),  3  (10.7%)  from 
the United Kingdom (48-50), 1 (3.6%) from Australia (51), 
and 1 (3.6%) from Japan (52). For studies conducted in 
the United States, the number of men screened ranged 
from 564 to 19.1 million; the number of biopsies performed 
ranged from 23 to 3.4 million; and the participants’ ages 
ranged  from  40  to  75  years  (Table  1).  For  studies  con-
ducted  in  other  industrialized  countries,  the  number  of 
men screened ranged from 472 to 533,402; the number of 
biopsies performed ranged from 29 to 45,873; and the par-
ticipants’ ages ranged from 40 to 93 years. A summary of 
the standardized resource costs for each screening method 
is in Table 2. Among these studies, only one conducted in 
the United States reported the resource cost of screening 
with F/t PSA and cPSA (39).
Baseline results 
For studies conducted in the United States, the pooled 
baseline  resource  cost  for  screening  with  PSA  obtained 
from  13  studies  was  $37.23,  and  the  pooled  baseline 
resource cost for screening with DRE obtained from eight 
studies  was  $31.77  (Table  3).  For  studies  conducted  in 
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Figure 1. Study selection process, Cost Analysis of Screening for, 
Diagnosing, and Staging Prostate Cancer, 1980–200. CaP indicates pros-
tate cancer; MeSH, medical subject headings.other  countries,  the  pooled  baseline  resource  cost  for 
screening with PSA from 10 studies was $30.92, and the 
pooled  baseline  resource  cost  for  screening  with  DRE 
obtained from eight studies was $33.54. 
For diagnostic tests and staging methods, the variations 
in the resource costs between the United States and other 
countries were mixed. The pooled baseline resource costs 
were 2.3 times higher for TRUS and 2.4 times higher for 
biopsy in the United States than in other countries. The 
pooled  baseline  resource  cost  of  a  urology  consultation 
was 1.3 times higher in other countries than in the United 
States. For clinical staging, the pooled baseline resource 
cost was 2.4 times higher in the United States than in 
other countries, but the pooled baseline costs for patho-
logic or histologic specimen analysis was 1.4 times higher 
in other countries.
For studies conducted in the United States, the weight-
ed  mean  cost  per  man  screened  with  PSA  was  $40.61 
(95% CI, $40.48–$40.74), compared with $34.82 (95% CI, 
$34.60–$35.05)  for  studies  conducted  in  other  countries 
(Figure 2). For diagnostic methods (Figure 3), the mean 
cost per man was $347.24 (95% CI, $347.05–$347.44) for 
U.S.  studies  compared  with  $292.51  (95%  CI,  $292.24–
$292.78) for non-U.S. studies. For clinical staging meth-
ods (Figure 4), the mean cost per man given a clinically 
staged diagnosis of prostate cancer was $322.11 (95% CI, 
$321.87–$322.34) for U.S. studies compared with $222.81 
(CI, $222.44–$223.19) for non-U.S. studies. The cost per 
analysis  of  pathologic  or  histologic  specimens  was  3.5 
times higher in other countries than in the United States.
In the United States, from 1993 to 2002, the average 
resource cost of screening with PSA decreased by $20.64 
(Figure  5).  In  addition,  from  1988  to  2002  the  average 
resource  cost  for  biopsy  decreased  by  $67.23.  However, 
the average costs for DRE, urology consultation, TRUS, 
pathologic or histologic analysis of a specimen, and clinical 
staging increased from the 1990s. In contrast, the average 
resource costs for all prostate cancer procedures or tests 
decreased in other industrialized countries (Figure 6). The 
highest decrease observed was for biopsy ($160.70), and 
the lowest was for DRE ($30.55).
Multivariate sensitivity analyses
The results of the Monte Carlo simulations are in Table 
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Figure 2. Weighted mean cost (in 200 U.S. dollars) per man screened for 
prostate cancer, by type of screening method. Numbers in brackets are the 
number of studies that reported on each testing method. Numbers in paren-
theses are 95% confidence intervals. Only U.S. studies reported costs for 
complex PSA or free/total PSA. 
Figure 3. Weighted mean cost (in 200 U.S. dollars) per man given a 
diagnostic test for prostate cancer, by diagnostic method. Numbers in brack-
ets are the number of studies that reported on each method. Numbers in 
parentheses are 95% confidence intervals. 
Figure 4. Weighted mean cost (in 200 U.S. dollars) per man given a clini-
cally staged diagnosis of prostate cancer. Numbers in brackets are the num-
ber of studies in each staging method. Numbers in parentheses are 95% 
confidence intervals. VOLUME 4: NO. 4
OCTOBER 2007
4. The estimated average resource costs of screening for, 
diagnosing,  and  clinically  staging  prostate  cancer  from 
studies conducted in the United States and other countries 
do not differ much from the baseline estimates in Table 
3, and the estimated 95% CIs are tight, an indication of 
the robustness of the baseline results. There is a slight 
variation in the estimated average resource cost for the 
histologic analysis of specimens from studies conducted in 
the other countries compared with the baseline.
For  studies  conducted  in  the  United  States,  the  esti-
mated median resource costs were $34.54 (interquartile 
range: $22.91–$49.75) for the PSA test and $234.7 (inter-
quartile range: $152.98–$432.67) for biopsy. These costs 
vary slightly from the baseline estimates. For studies con-
ducted in other industrialized countries, the median cost 
of a urology consultation was $92.95 (interquartile range: 
$74.68–$114.81) and $100.56 (interquartile range: $80.92–
$125.25) for TRUS. These costs do not differ substantially 
from the baseline estimates; however, the median cost for 
clinical staging in non-U.S. countries differs substantially 
from baseline with an estimated resource cost of $288.25 
(interquartile range: $217.42–$380.62).
Discussion
Both U.S. and non-U.S. studies estimated the resource 
costs for screening with PSA and DRE to be greater than 
$30.  We  found  little  variation  in  the  resource  costs  of 
screening for prostate cancer between the United States 
and other industrialized countries; however, the resource 
costs  for  diagnostic  and  staging  methods  were  mixed. 
Furthermore, we found that the weighted mean cost per 
man for screening for, diagnosing, and clinically staging 
prostate  cancer  varied  between  the  United  States  and 
other industrialized countries. Over time, the changes in 
the average resource costs in U.S. studies were mixed (some 
increased, and some decreased), but they all decreased in 
studies conducted in other industrialized countries.
In general, our findings on resource costs of testing meth-
ods  are  consistent  with  previously  published  estimates. 
For example, in 2002 O’Malley and colleagues estimated 
the resource costs (including cost of the testing method, 
consumables,  and  personnel)  for  screening to  be  $34 
with PSA and $20 with DRE (53). When these costs were 
adjusted to 2003 U.S. dollars, the estimates were close, 
with the exception of resource costs for DRE. Compared 
with the O’Malley study, our estimate of resource costs 
for DRE is about 31% higher for studies conducted in the 
United States and 34% higher for studies conducted in 
other countries. One explanation for this difference could 
be  the  differences  in  the  resource  measurement  used. 
Because DRE is performed as part of a general physical 
examination, some studies included the resource cost for a 
physician visit as part of the cost of DRE (35,36,46). One 
study estimated that the resource costs attributed to DRE 
were 13.3% of the total for a physician visit (36), whereas 
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Figure 5. Average changes in resource cost by screening test, diagnostic 
test, and staging of prostate cancer according to studies conducted in the 
United States, in 200 U.S. dollars.
Figure 6. Average changes in resource cost, by screening and diagnostic 
tests for prostate cancer according to studies conducted in industrialized 
countries other than the United States, in 200 U.S. dollars. two studies assumed that the resource cost for perform-
ing DRE is zero because it is part of the routine annual 
physical examination (27,34). Furthermore, our estimated 
resource costs for testing with PSA were within the range 
of the price ($30–$60) reported in the news media (54).
The resource costs for TRUS, biopsy, and clinical staging 
were at least 2.3 times higher in the United States than in 
other countries. This finding is consistent with the general 
belief that medical technology is more expensive in the 
United States than in other industrialized nations (55). 
Although medical technology may cost more in the United 
States  than  elsewhere,  the  resource  costs  for  urology 
consultation and pathologic or histologic analysis of speci-
mens are at least 1.3 times higher in other countries. For 
urology consultation, the differences in the resource costs 
may be explained by differences in the measurement of 
resource inputs included in the calculation. For example, 
four of five studies conducted in other countries that met 
the  inclusion  criteria  for  urology  consultation  included 
resource costs such as telephone calls, nurse and secretary 
wages, and hospital visits (42,46,47,50). Other sources of 
variation could be differences in study settings.
Currently,  the  evidence  is  insufficient  to  determine 
whether  early  detection  of  prostate  cancer  is  cost-effec-
tive. The conclusions of the few studies that reported the 
cost-effectiveness of prostate cancer screening vary widely 
(12-14). As a result, these economic studies may not inform 
policy. Several economic studies reported that costs are 
the major source of variation in differing conclusions for 
cost-effectiveness of health interventions (56-59). A recent 
workshop at the Institute of Medicine concluded that poor 
quality of information on resource costs of screening pro-
cedures is a major source of the inconsistency in results 
among  several  models  of  cost-effectiveness  of  colorectal 
cancer screening (60). In 1996, the United States Panel on 
Cost-Effectiveness in Health and Medicine recommended 
the use of resource-based cost in estimating the cost-effec-
tiveness of health interventions (17). The purpose of this 
recommendation was to promote transparency and gen-
eralizability in the use of economic evaluation results to 
inform policy. The components of resource costs for early 
detection of prostate cancer identified in studies included 
in this paper are patients’ travel time, loss of work time, 
loss of leisure time, transportation cost, physicians’ con-
sultation time, other medical staff time, medical supplies, 
office or room space, equipment, patient recruitment, and 
other consumables. The range of resource costs included in 
a particular study depends on the perspective of the study. 
Because our study took a societal perspective, we chose 
all identified resource costs. We believe that the pooled 
resource costs reported in this article may contribute to 
promoting transparency and generalizability of economic 
studies on prostate cancer within and among countries.
Screening by PSA remains controversial because of the 
lack of scientific evidence from clinical trials demonstrat-
ing that early detection reduces mortality. In recent years, 
several variations of the PSA test have been developed 
that may improve the test’s specificity and may reduce 
the biopsy rate (61-64). These newer testing technologies 
include free PSA, F/tPSA, cPSA, and PSA density. Among 
the variations of the PSA test, we were able to find only 
one U.S. study reporting F/tPSA and cPSA data that met 
our inclusion criteria (39). The resource costs for these two 
newer testing methods were $41.56 for F/tPSA and $21.78 
for cPSA.
The diagnostic methods considered in our study were 
TRUS and biopsy. The literature reports that TRUS can 
be used to screen for prostate cancer, to estimate the size 
of the prostate, to diagnose cancer, and to guide needle 
biopsies (65). Although earlier studies evaluated TRUS as 
a tool for prostate cancer screening (27,31,32,34), it has 
not been shown to be an effective screening test (66-69). 
Currently, TRUS is used primarily to image the prostate 
gland and to guide needle biopsy. For these reasons, we 
defined TRUS as a diagnostic method. We also assert that 
this definition is a matter of formality since resource costs 
were reported separately and not as combined resource 
costs of diagnosing prostate cancer.
Biopsy is currently the gold standard method for diag-
nosing  prostate  cancer  (66).  Several  biopsy  procedures 
can  confirm  the  diagnosis  of  prostate  cancer  (7,49,64). 
Therefore, we combined the resource costs of these biopsy 
procedures because many of the studies reviewed reported 
aggregated resource cost for each procedure.
The final method in the evaluation and management of 
prostate cancer, clinical staging, is important because it 
is the first step in determining prognosis and because it 
guides treatment decisions for men with an established 
diagnosis  of  cancer.  In  most  of  the  studies  reviewed, 
the  researchers  used  different  types  of  clinical  staging 
procedures.  For  example,  Gottlieb  et  al  used  CT,  MRI, 
and  radionuclide  bone  scan  (36).  As  with  biopsy,  some 
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researchers reported combined resource costs for clinical 
staging. Therefore, the resource cost we report is a combi-
nation of resource costs for various procedures.
Our study has limitations. Most of these are primarily 
tied to the limitations in the studies we reviewed. First, 
the reported resource costs were pooled from studies con-
ducted with different populations and in different settings 
and  should  be  interpreted  with  caution.  However,  we 
conducted  appropriate  sensitivity  analyses  using  Monte 
Carlo simulation to assess the robustness of the baseline 
results. Second, PSA is used as a screening test, a diag-
nostic tool, and a biological marker to follow the progress 
of disease in men with prostate cancer, but we did not dis-
tinguish reported resource costs for PSA among its uses. 
We are not sure whether this lack of distinction may have 
underestimated  or  overestimated  the  reported  resource 
costs for PSA. Third, for some studies it was difficult to 
separate the resource cost of performing DRE from that of 
the physician visit. Because of the strong interaction, we 
may have overestimated resource costs for DRE. Fourth, 
because reported resource costs for performing biopsy and 
clinical staging represented combined resource costs from 
several procedures, they should be interpreted with cau-
tion. Furthermore, reported resource costs for performing 
TRUS or biopsy did not include the cost of complications 
resulting from these procedures. It has been reported that 
complication costs are directly correlated to the biopsy rate 
(70). Gustafsson et al suggest that the resource costs asso-
ciated  with  complications  arising  from  TRUS  or  biopsy 
should be reported separately from those for diagnostic 
procedures (46) because the cost of complications depends 
on the number of infections, which ranges from 5% to 6%, 
and  their  severity  (71,72).  Fifth,  for  studies  conducted 
in other countries, we are not sure if the resource costs 
reported by some authors were costs or charges. If some 
resources are charges rather than costs, then the pooled 
resource  costs  presented  here  for  studies  conducted  in 
other countries may be lower than we report.
Finally, identifying and measuring all the resources used 
in screening for, diagnosing, and clinically staging pros-
tate cancer is a time-consuming and expensive process. 
In many situations, such detailed evaluations may not be 
practical. Therefore, the resource cost estimates reported 
will  invariably  diverge  from  the  microcosting  approach 
recommended by the U.S. Panel on Cost-Effectiveness in 
Health and Medicine (17).
To examine the policy implications of resource cost esti-
mates reported here for decision making, we assumed the 
worst-case scenario in which 50 million men aged 40 to 74 
years in the United States (73) receive a PSA test annu-
ally. Using the baseline societal resource cost estimate of 
$37.23 per test, this would translate approximately into 
an undiscounted $1.86 billion per year. Of course, this esti-
mate may not be realistic given that not all eligible men in 
the population would be tested annually. Similarly, it may 
be difficult to justify screening men aged 40 to 49 years in 
the entire population unless there is a family history of 
prostate cancer or the man is of African American descent. 
This  example  illustrates  how  the  results  presented  in 
this paper may be used by policy makers in making deci-
sions  regarding  resource  allocation  for  prostate  cancer. 
Similarly, researchers may use the resource cost estimates 
presented in this paper as one of the input variables in 
estimating the cost-effectiveness of screening for prostate 
cancer and detecting it early.  
The  effectiveness  of  early  detection  in  reducing  the 
mortality associated with prostate cancer is still a mat-
ter of debate. With limited health resources, investing in 
early-detection  services  for  prostate  cancer  will  require 
an understanding of resource costs used in estimating the 
economic cost of this disease. Therefore, realistic resource 
cost  estimates  are  necessary  to  calculate  meaningful 
cost-effectiveness estimates for prostate cancer screening, 
diagnosing, and staging. Our analysis may benefit health 
policy makers charged with allocating resources to pros-
tate cancer.
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Tables
Table 1. Characteristics of Prostate Cancer Studies Reviewed, United States and Other Industrialized Countries, 1980–2003
Study
Base 
Yeara No. Men Tested
No. Biopsies 
Performed
No. Cancers 
Detected
Age of Men 
Tested, y Study Setting
Studies conducted in the United States
Torp-Pedersen et al (26) 1988 784 9 0 Not reported Multi-institutional study in the 
United States
Optenberg et al (14) 1988 17,496,288 NR 24,229 50-70 NR
Babaian et al (27) 1992 1,860 46 170 6 M.D. Anderson Cancer Center
Dorr et al (28) 1992 19,19,490 ,42,842 1,047,695 50-75 NR
Kramer et al (29) 1990 18,856,40 NR 654,05 50-74 NR
Littrup et al (0) 1992 2,425 271 129 55-70 ACS-NPCDP study
Abramson et al (1) 1992 564 119 18 40-75 Baptist Medical Center, 
Jacksonville, Florida
Benoit et al (2)b 1992  5,40 825 177 50-69 Multicenter study
8,529 69 209 50-70 Washington University study
Krahn et al () 1992 NR NR NR 50-70 NR
Kantrowitz et al (4) 1995 1,219 2 12 50-65 Polaroid Corp, work site
OTA (5) 1992 18,00 NR 626 65-75 NR
Gottlieb et al (6) 1995 NR NR NR  50-70 NR
Snyder et al (7) 1995 788 52 1 40-75 Zeneca Pharmaceutical Corp, 
work site
Weinrich et al (8) 2001 892 2 10 40-70 Work sites and churches in 11 
South Carolina counties
Ellison et al (9) 2001 2,18 NR 620 40-75 Multiple sites (e.g., UroCor 
Laboratories and Bayer 
Diagnostics) 
NR indicates not reported; ACS–NPCDP American Cancer Society–National Prostate Cancer Detection Project; OTA, Office of Technology Assessment. 
a The year in which the data used in the study were collected. 
b This study was conducted in more than one setting. We report the figures for each setting separately. The multicenter study was done at the University of 
California and in Canada. 
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Study
Base 
Yeara No. Men Tested
No. Biopsies 
Performed
No. Cancers 
Detected
Age of Men 
Tested, y Study Setting
Studies conducted in other industrialized countries
Carlsson et al (44) 1987 1,16 44 1 50-69 Municipal residence in Norrkoping, 
Sweden
Pedersen et al (45) 1989 1,16 45 1 50-69 Norrkoping, Sweden
Chadwich et al (48) 1990 472 29 7 55-70 Large city general practice, United 
Kingdom
Green et al (40) 1992 ,627 NR NR 50-70 Setting not reported, Canada
Labrie et al (41) 199 7,50 761 252 45-80 Laval Univ Prostate Cancer 
Detection Program, Canada
Gustafsson et al (46) 1990 1,782 41 65 55-70 Soder Hospital, Stockholm, 
Sweden
Chamberlain et al (49) 1995 NR NR NR NR Setting not reported, United 
Kingdom
Holmberg et al (47) 1996 1,492 NR 4 50-69 Norrkoping, Sweden
Perkins et al (51) 1995 474 NR NR 40-79 New South Wales, Australia
Krahn et al (42) 1995 5,402 45,87 9,074 50-74 National survey of Canadian men, 
population-based
Candas et al (4) 1998 9,296 91 282 45-80 Quebec City, Canada
Kosuda et al (52) 2001 NR NR 1294 42-9 Multicenter study of five working 
group hospitals, Japan
Donovan et al (50) 2001 7,8 592 165 50-69 Setting not reported, United 
Kingdom
 
NR indicates not reported; ACS–NPCDP American Cancer Society–National Prostate Cancer Detection Project; OTA, Office of Technology Assessment. 
a The year in which the data used in the study were collected. 
b This study was conducted in more than one setting. We report the figures for each setting separately. The multicenter study was done at the University of 
California and in Canada. 
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Table 2. Standardized Resource Costs for Prostate Cancer Screening, Diagnosing, and Staging, in U.S. Dollars, United States 
and Other Industrialized Countries, 1980–2003
Study
Testing Methodsa Diagnostic Methods Staging Methods
 PSA F/t PSA cPSA DRE
Urology 
Consultb,c TRUS Biopsyd
Pathologic 
or 
Histologicc Clinicale
Studies conducted in the United Statesf
Torp-Pedersen et al 
(26)g
 NR NR NR  NR 44.48 211.51 00.46
197.67 
NR NR
Optenberg et al (14)  NR NR NR  NR NR NR 245.57 66.27 676.94
Babaian et al (27) 45.8 NR NR 0.00 NR 147.06 105.04 84.04 NR
Dorr et al (28) 57.68 NR NR   NR NR 280.55 41.65 NR 197.86
Kramer et al (29) 2.0 NR NR 41.94 NR NR 19.81 NR 507.06
Littrup et al (0) 9. NR NR 9. NR 196.65 655.50 NR 910.27
Abramson et al (1) 2.78 NR NR 2.78 98. 11.10 150.77 11.10 NR
Benoit et al (2) 24.67 NR NR 4.20 58.51 71.90 105.46 45.77 NR
Krahn et al () 1.11 NR NR 0.00 — 159.94 08.09 81.28 1,067.15
Kantrowitz et al (4) 5.50 NR NR 12.58 156.04 488.84 64.50 NR NR
Office of Tech- 
nology Assess- 
ment (5)
24.84 NR NR 26.05 9.60 71.8 158.96 105.04 1,097.5
Gottlieb et al (6) 4.94 NR NR   NR NR NR 489.20 NR 698.85
Snyder et al (7) 54.54 NR NR 5.78 76.25 445.74 1,92.72 NR NR
Weinrich et al (8) 77.18 NR NR 61.48 65.18 404.5 549.19 NR NR
Ellison et al (9) 20.78 41.56 20.78   NR NR NR 181.8 145.46 NR
Studies conducted in other industrialized countriesh
Carlsson et al (44)   NR NR NR 66.66 NR  NR 240.00 128.22  NR
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NR indicates not reported; TRUS, transrectal ultrasound 
a PSA indicates prostate-specific antigen; F/t PSA, free/total PSA; cPSA, complex PSA; DRE, digital rectal examination. 
b Any consultation or referral to a urologist, clinical oncologist, or any other specialist. 
c Urology consultation and pathologic or histologic analysis of specimen are process measures, not methods. 
d Resource costs of biopsy include costs for core-needle, TRUS-guided fine-needle aspiration, needle, and transrectal needle.  
e Resource cost of clinical staging procedures includes computed tomography (CT), magnetic resonance imaging (MRI), radionuclide bone scan, pelvic lymph 
node excision and analysis, and pelvic echography.  
f All resource costs were standardized to 200 U.S. dollars using the Consumer Price Index (CPI) for the year that cost data were collected. In addition, all 
costs that were originally presented as charges (prices), which may not reflect the true resource cost of providing prostate cancer-related services, were con-
verted to cost by using a cost-to-charge ratio.  
g The $00.46 figure is the real cost of performing biopsies at institutions in six states: New York, California, Alabama, Massachusetts, Arizona, and Texas. 
The researchers found that the the charges at another institution in southeastern Michigan were reported as $197.67. The two figures cannot be combined 
since charges are not the same as costs. 
h Canada, Australia, Japan, Sweden, and the United Kingdom. All resource costs were standardized to 200 U.S. dollars using the country-specific 
Consumer Price Index for the year that cost data were collected and the Purchasing Power Parity method. 
(Continued on next page)Study
Testing Methodsa Diagnostic Methods Staging Methods
 PSA F/t PSA cPSA DRE
Urology 
Consultb,c TRUS Biopsyd
Pathologic 
or 
Histologicc Clinicale
Studies conducted in other industrialized countriesh (continued)
Pedersen et al (45)  NR NR NR 40.70  NR NR 194.60  NR  NR
Chadwich et al (48) 46.5 NR NR NR NR NR 1.64 59.8 NR
Green et al (40) 25.76 NR NR NR NR NR  NR  NR  NR
Labrie et al (41) 24.67 NR NR 24.67  NR NR 197.40 NR NR
Gustafsson et al 
(46)
69.00 NR NR 5.41 147.84 NR 226.55 95.74 NR
Chamberlain et al 
(49)
6.54 NR NR 21.94  NR NR NR NR NR
Holmberg et al (47) 14.67 NR NR 16.1 101.56 NR 12.67  NR 146.74
Perkins et al (51) 17.61 NR NR 21.68 55.61 87.7 NR  NR NR
Krahn et al (42) 5.69 NR NR  NR 79.57 NR 298.51 241.1 168.79
Candas et al (4) 2.1 NR NR 2.1  NR 185.04 115.65  NR  NR
Kosuda et al (52) 15.56 NR NR  NR  NR 8.91 56.60 NR 60.67
Donovan et al (50)    NR NR NR  NR 100.61  NR  NR NR NR
 
NR indicates not reported; TRUS, transrectal ultrasound 
a PSA indicates prostate-specific antigen; F/t PSA, free/total PSA; cPSA, complex PSA; DRE, digital rectal examination. 
b Any consultation or referral to a urologist, clinical oncologist, or any other specialist. 
c Urology consultation and pathologic or histologic analysis of specimen are process measures, not methods. 
d Resource costs of biopsy include costs for core-needle, TRUS-guided fine-needle aspiration, needle, and transrectal needle.  
e Resource cost of clinical staging procedures includes computed tomography (CT), magnetic resonance imaging (MRI), radionuclide bone scan, pelvic lymph 
node excision and analysis, and pelvic echography.  
f All resource costs were standardized to 200 U.S. dollars using the Consumer Price Index (CPI) for the year that cost data were collected. In addition, all 
costs that were originally presented as charges (prices), which may not reflect the true resource cost of providing prostate cancer-related services, were con-
verted to cost by using a cost-to-charge ratio.  
g The $00.46 figure is the real cost of performing biopsies at institutions in six states: New York, California, Alabama, Massachusetts, Arizona, and Texas. 
The researchers found that the the charges at another institution in southeastern Michigan were reported as $197.67. The two figures cannot be combined 
since charges are not the same as costs. 
h Canada, Australia, Japan, Sweden, and the United Kingdom. All resource costs were standardized to 200 U.S. dollars using the country-specific 
Consumer Price Index for the year that cost data were collected and the Purchasing Power Parity method. 
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Table 3. Pooled Resource Costs for Prostate Cancer Screening, Diagnosing, and Staging, in U.S. Dollars, United States and 
Other Industrialized Countries, 1980–2003
Method [No. Studies Using Method]
Pooled Resource Costs,  
2003 U.S. $
 Probability 
Distributiona Baseline Min Max
Studies conducted in the United States
Screening
Prostate-specific antigen (PSA) [1] 7.2 1.11 77.18 Triangular
Free/total PSA [1] 41.56 20.78 62.4 Triangular
Complex PSA [1] 20.78 10.9 41.56 Triangular
Digital rectal examination [8] 1.77 4.20 61.48 Normal
Diagnostic 
Urology consult b,c [7] 76.91 9.60 156.04 Normal
Transrectal ultrasound [11] 27.18 71.8 488.84 Normal
Biopsy [15] d 9.09 105.04 1,92.72 Invgauss
Staging
Pathologic or histologic [7]c 94.14 45.77 145.46 Log normal
Clinical staging [7]e 76.52 197.86 1,097.5 Normal
Studies conducted in other industrialized countriesf
Screening
Prostate-specific antigen (PSA) [10] 0.92 15.56 69.00 Normal
Free/total PSA [0] NR NR NR NR
Complex PSA [0] NR NR NR NR
Digital rectal examination [8] .54 16.1 66.66 Normal
Diagnostic 
Urology consultation [5] b,c 97.04 55.61 147.84 Log normal
Transrectal ultrasound [] 10.77 8.91 185.04 Triangular
Biopsy [9] d 164.96 1.64 298.51 Normal
Staging 
Pathologic or histologic [4]c 11.2 59.8 241.1 Uniform
Clinical staging [] e 06.40 146.74 60.67 Triangular
 
NR indicates not reported; TRUS, transrectal ultrasound 
a Probability distributions used in conducting multivariate sensitivity analysis. 
b Urology consult was defined as any consultation or referral to a urologist, clinical oncologist, or any other specialist. 
c Urology consultation and pathologic or histologic analysis of specimen are process measures, not methods. 
d Resource costs of biopsy include costs for core needle, TRUS-guided, fine-needle aspiration, needle, and transrectal needle. 
e Resource costs of clinical staging procedures include computed tomography, magnetic resonance imaging, radionuclide bone scan, pelvic lymph node exci-
sion and analysis, and echography.  
f Canada, Australia, Japan, Sweden, and the United Kingdom.VOLUME 4: NO. 4
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Table 4. Multivariate Sensitivity Analyses from Monte Carlo Simulations, Estimated Average Resource Costs for Methods of 
Prostate Cancer Screening, Diagnosing, and Staging, United States and Other Industrialized Countries, 1980–2003
Method
    Studies in the United States     Studies in Other Industrialized Countriesa
Mean (95% CI) Median
Interquartile 
Range Mean (95% CI) Median
Interquartile 
Range
2003 $
Screening
Prostate-specific anti-
gen (PSA)
7.55 (6.48-8.62) 4.54 (22.91-49.75) 0.92 (29.87-1.97) 0.91 (19.56-42.24)
Free/total PSA 41.56 (41.0-42.09) 41.56 (5.47-47.6) NR NR NR
Complex PSA 24.24 (2.64-24.64) 2.56 (19.9-28.8) NR NR NR
Digital rectal exami-
nation
1.77 (0.67-2.88) 1.7 (19.7-4.76) .56 (2.4-4.69) .51 (21.26-45.79)
Diagnostic
Urology 
consultationb,c
76.91 (74.4-79.9) 76.84 (49.78-10.89) 97.06 (95.12-99.00) 92.95 (74.68-114.81)
Transrectal ultra-
sound
27.15 (227.97-246.) 26.92 (17.12-6.85) 10.77 (101.89-105.66) 100.56 (80.92-125.25)
Biopsyd 92.8 (64.61-421.04) 24.70 (152.98-42.67) 164.92 (159.42-170.42) 164.76 (105.11-224.58)
Staging
Pathologic or histo-
logicc
94.14 (92.07-96.21) 90.74 (70.-114.14) 19.04 (17.24-140.84) 18.97 (11.85-164.1)
Clinicale 76.56 (716.66-756.45) 76.24 (519.11-952.25) 06.4 (299.88-12.9) 288.25 (217.42-80.62)
 
NR indicates not reported; TRUS, transrectal ultrasound 
a Canada, Australia, Japan, Sweden, and the United Kingdom. 
b Urology consultation was defined as any consultation or referral to a urologist, clinical oncologist, or any other specialist. 
c Urology consult and pathologic or histologic analysis of specimen are process measures, not methods. 
d Resource costs of biopsy include costs for core needle, TRUS-guided, fine-needle aspiration, needle, and transrectal needle. 
e Resource cost of clinical staging procedures included computed tomography, magnetic resonance imaging, radionuclide bone scan, pelvic lymph node exci-
sion and analysis, and pelvic echography.